Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Anticonvulsant and neurotoxic effects of a novel 1,2,4-triazole-3-thione derivative (TPF-34) and its isobolographic interaction profile with classical antiepileptic drugs in mice.

Łuszczki JJ, Lepiech J, Zagaja M, Wróblewska-Łuczka P, Florek-Łuszczki M, Bojar H, Walczak A, Plech T.

Pharmacol Rep. 2020 Feb;72(1):87-95. doi: 10.1007/s43440-019-00044-7. Epub 2019 Dec 20.

PMID:
32016835
2.

Health Behaviours in Scaffold Use Risk Assessment Model - SURAM.

Bojar H, Silveira F, Rebelo M, Elżbieta C, Krzysztof C.

Ann Agric Environ Med. 2019 Mar 22;26(1):138-142. doi: 10.26444/aaem/100534. Epub 2019 Jan 3.

3.

Contamination of selected recreational areas in Lublin Province, Eastern Poland, by eggs of Toxocara spp., Ancylostoma spp. and Trichuris spp.

Bojar H, Kłapeć T.

Ann Agric Environ Med. 2018 Sep 25;25(3):460-463. doi: 10.26444/aaem/92252. Epub 2018 Aug 8.

4.

Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2.

Kleef R, Moss R, Szasz AM, Bohdjalian A, Bojar H, Bakacs T.

Integr Cancer Ther. 2018 Dec;17(4):1297-1303. doi: 10.1177/1534735418794867. Epub 2018 Sep 7. Erratum in: Integr Cancer Ther. 2019 Jan-Dec;18:1534735419854816.

5.

Tawny owl (Strix aluco) as a potential transmitter of Enterobacteriaceae epidemiologically relevant for forest service workers, nature protection service and ornithologists.

Grzywaczewski G, Kowalczyk-Pecka D, Cios S, Bojar W, Jankuszew A, Bojar H, Kolejko M.

Ann Agric Environ Med. 2017 Mar 31;24(1):62-65. doi: 10.5604/12321966.1230732.

6.

NEW ASPECTS REGARDING NEOADJUVANT RADIOCHEMOTHERAPY IN LOCALLY ADVANCED NONINFLAMMATORY BREAST CANCER AND PREDICTIVE FACTORS FOR A PATHOLOGIC COMPLETE REMISSION: IGCS-0016 Breast Cancer.

Matuschek C, Boelke E, Budach W, Speer V, Bojar H, Audretsch W, Nestle K.

Int J Gynecol Cancer. 2015 May;25 Suppl 1:1. No abstract available.

PMID:
25955892
7.

Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer.

Poremba C, Uhlendorff J, Pfitzner BM, Hennig G, Bohmann K, Bojar H, Krenn V, Brase JC, Haufe F, Averdick M, Dietel M, Kronenwett R, Denkert C.

Virchows Arch. 2014 Oct;465(4):409-17. doi: 10.1007/s00428-014-1652-0. Epub 2014 Sep 14.

8.

Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: a pilot study.

Matuschek C, Lehnhardt M, Gerber PA, Poremba C, Hamilton J, Lammering G, Orth K, Budach W, Bojar H, Bölke E, Peiper M.

Eur J Med Res. 2014 Feb 3;19:6. doi: 10.1186/2047-783X-19-6.

9.

Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer.

Darb-Esfahani S, Kronenwett R, von Minckwitz G, Denkert C, Gehrmann M, Rody A, Budczies J, Brase JC, Mehta MK, Bojar H, Ataseven B, Karn T, Weiss E, Zahm DM, Khandan F, Dietel M, Loibl S.

Br J Cancer. 2012 Nov 20;107(11):1892-900. doi: 10.1038/bjc.2012.475. Epub 2012 Oct 18.

10.

Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for a pathologic complete remission : results of a multivariate analysis.

Matuschek C, Bölke E, Roth SL, Orth K, Lang I, Bojar H, Janni JW, Audretsch W, Nestle-Kraemling C, Lammering G, Speer V, Gripp S, Gerber PA, Buhren BA, Sauer R, Peiper M, Schauer M, Dommach M, Struse-Soll K, Budach W.

Strahlenther Onkol. 2012 Sep;188(9):777-81. Epub 2012 Aug 11.

PMID:
22878547
11.
12.

A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors.

Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenführer J, Hengstler JG.

Clin Cancer Res. 2012 May 1;18(9):2695-703. doi: 10.1158/1078-0432.CCR-11-2210. Epub 2012 Feb 20.

13.

Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients.

Matuschek C, Rudoy M, Peiper M, Gerber PA, Hoff NP, Buhren BA, Flehmig B, Budach W, Knoefel WT, Bojar H, Prisack HB, Steinbach G, Shukla V, Schwarz A, Kammers K, Erhardt A, Scherer A, Bölke E, Schauer M.

Eur J Med Res. 2011 Oct 10;16(10):451-6.

14.

Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease.

Matuschek C, Bölke E, Lammering G, Gerber PA, Peiper M, Budach W, Taskin H, Prisack HB, Schieren G, Orth K, Bojar H.

Eur J Med Res. 2010;15:277-86.

15.

Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer : survival advantage in cT2 category by neoadjuvant radiochemotherapy.

Roth SL, Audretsch W, Bojar H, Lang I, Willers R, Budach W.

Strahlenther Onkol. 2010 Jun;186(6):299-306. doi: 10.1007/s00066-010-2143-0. Epub 2010 May 21.

PMID:
20495968
16.

[Nitazoxanide ("Alinia")--a promising antiparasitic drug].

Bojar H, Knap JP.

Wiad Parazytol. 2010;56(1):11-8. Review. Polish.

PMID:
20450003
17.

ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.

Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, Hellwig B, Rahnenführer J, Hengstler JG, Gehrmann MC.

Clin Cancer Res. 2010 Apr 15;16(8):2391-401. doi: 10.1158/1078-0432.CCR-09-2471. Epub 2010 Apr 6.

18.

Gene expression of circulating tumour cells in breast cancer patients.

Bölke E, Orth K, Gerber PA, Lammering G, Mota R, Peiper M, Matuschek C, Budach W, Rusnak E, Shaikh S, Dogan B, Prisack HB, Bojar H.

Eur J Med Res. 2009 Sep 28;14(10):426-32.

19.

Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients.

Bölke E, Orth K, Gerber PA, Lammering G, Mota R, Peiper M, Matuschek C, Budach W, Rusnak E, Shaikh S, Dogan B, Prisack HB, Bojar H.

Eur J Med Res. 2009 Aug 12;14(8):359-63.

20.

ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis.

Mirmohammadsadegh A, Mota R, Gustrau A, Hassan M, Nambiar S, Marini A, Bojar H, Tannapfel A, Hengge UR.

J Invest Dermatol. 2007 Sep;127(9):2207-15. Epub 2007 May 17.

21.
22.

Can a 70-gene signature provide useful prognostic information in patients with node-negative breast cancer?

Modlich O, Bojar H.

Nat Clin Pract Oncol. 2007 Apr;4(4):216-7. Epub 2007 Feb 6. No abstract available.

PMID:
17290242
23.

Expression analysis of pancreatic cancer cell lines reveals association of enhanced gene transcription and genomic amplifications at the 8q22.1 and 8q24.22 loci.

Domagk D, Schaefer KL, Eisenacher M, Braun Y, Wai DH, Schleicher C, Diallo-Danebrock R, Bojar H, Roeder G, Gabbert HE, Domschke W, Poremba C.

Oncol Rep. 2007 Feb;17(2):399-407.

PMID:
17203180
24.

Breast cancer expression profiling: the impact of microarray testing on clinical decision making.

Modlich O, Prisack HB, Bojar H.

Expert Opin Pharmacother. 2006 Oct;7(15):2069-78. Review.

PMID:
17020433
25.

Gene expression in acute Stanford type A dissection: a comparative microarray study.

Weis-Müller BT, Modlich O, Drobinskaya I, Unay D, Huber R, Bojar H, Schipke JD, Feindt P, Gams E, Müller W, Goecke T, Sandmann W.

J Transl Med. 2006 Jul 6;4:29.

26.

STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases.

Mirmohammadsadegh A, Hassan M, Bardenheuer W, Marini A, Gustrau A, Nambiar S, Tannapfel A, Bojar H, Ruzicka T, Hengge UR.

J Invest Dermatol. 2006 Oct;126(10):2272-80. Epub 2006 Jun 1.

27.

Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy.

Prisack HB, Karreman C, Modlich O, Audretsch W, Danae M, Rezai M, Bojar H.

Anticancer Res. 2005 Nov-Dec;25(6C):4615-21.

29.

Immunotherapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL-23/IL-18 gene transfer in a rat osteosarcoma model.

Liebau C, Roesel C, Schmidt S, Karreman C, Prisack JB, Bojar H, Merk H, Wolfram N, Baltzer AW.

Anticancer Res. 2004 Sep-Oct;24(5A):2861-7.

30.

Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease.

Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H.

Clin Cancer Res. 2004 Oct 1;10(19):6418-31.

31.

Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles.

Modlich O, Prisack HB, Pitschke G, Ramp U, Ackermann R, Bojar H, Vögeli TA, Grimm MO.

Clin Cancer Res. 2004 May 15;10(10):3410-21.

32.

Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector.

Rohr UP, Wulf MA, Stahn S, Heyd F, Steidl U, Fenk R, Opalka B, Pitschke G, Prisack HB, Bojar H, Haas R, Kronenwett R.

Cancer Gene Ther. 2003 Dec;10(12):898-906.

PMID:
14712316
33.

Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells.

Liebau C, Merk H, Schmidt S, Roesel C, Karreman C, Prisack JB, Bojar H, Baltzer AW.

Cytokines Cell Mol Ther. 2002;7(4):135-42.

PMID:
14660053
34.

rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid: a new option as immuno-therapy for osteosarcoma?

Liebau C, Merk H, Roesel C, Schmidt S, Karreman C, Prisack JB, Bojar H, Baltzer AW.

Anticancer Res. 2002 Sep-Oct;22(5):2559-65.

PMID:
12529964
35.

Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families.

Balz V, Prisack HB, Bier H, Bojar H.

Cancer Genet Cytogenet. 2002 Oct 15;138(2):120-7.

PMID:
12505256
36.

Gene expression profiles in the acutely dissected human aorta.

Müller BT, Modlich O, Prisack HB, Bojar H, Schipke JD, Goecke T, Feindt P, Petzold T, Gams E, Müller W, Hort W, Sandmann W.

Eur J Vasc Endovasc Surg. 2002 Oct;24(4):356-64.

37.
38.

Effects of tamoxifen on human squamous cell carcinoma lines of the head and neck.

Hoffmann TK, Bojar H, Eckel J, van Lierop A, Balz V, Friebe-Hoffmann U, Hauser U, Bier H.

Anticancer Drugs. 2002 Jun;13(5):521-31.

PMID:
12045464
39.

Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma.

Liebau C, Baltzer AW, Schmidt S, Roesel C, Karreman C, Prisack JB, Bojar H, Merk H.

Anticancer Res. 2002 Mar-Apr;22(2A):931-6.

PMID:
12014674
40.

Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells.

Steidl U, Kronenwett R, Rohr UP, Fenk R, Kliszewski S, Maercker C, Neubert P, Aivado M, Koch J, Modlich O, Bojar H, Gattermann N, Haas R.

Blood. 2002 Mar 15;99(6):2037-44.

PMID:
11877277
41.

Local inflammation and devascularization--in vivo mechanisms of the "bystander effect" in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma.

Floeth FW, Shand N, Bojar H, Prisack HB, Felsberg J, Neuen-Jacob E, Aulich A, Burger KJ, Bock WJ, Weber F.

Cancer Gene Ther. 2001 Nov;8(11):843-51.

42.

Novel lipophilic chloroquine analogues for a highly efficient gene transfer into gynecological tumors.

Keil O, Bojar H, Prisack HB, Dall P.

Bioorg Med Chem Lett. 2001 Oct 8;11(19):2611-3.

PMID:
11551761
43.

Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF.

Schmoor C, Sauerbrei W, Bastert G, Bojar H, Schumacher M; German Breast Cancer Study Group.

Eur J Cancer. 2001 Jun;37(9):1123-31.

PMID:
11378343
44.

The Estrogen Receptor Paradox in Breast Cancer: Association of High Receptor Concentrations with Reduced Overall Survival.

Struse K, Audretsch W, Rezai M, Pott G, Bojar H.

Breast J. 2000 Mar;6(2):115-125.

PMID:
11348346
45.

Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast-cancer patients. The German Breast-Cancer Study Group.

Schmoor C, Bastert G, Dunst J, Bojar H, Christmann D, Unbehaun V, Tümmers G, Bauer W, Sauerbrei W, Schumacher M.

Int J Cancer. 2000 May 1;86(3):408-15.

46.
47.

Gene Therapy for Treatment of Brain Tumors (HSV-tKIn Vivo Gene Transfer) : A Case Study.

Weber F, Floeth F, Bojar H.

Methods Mol Med. 2000;35:499-509. doi: 10.1385/1-59259-086-1:499.

PMID:
21390826
48.

Modelling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG).

Sauerbrei W, Royston P, Bojar H, Schmoor C, Schumacher M.

Br J Cancer. 1999 Apr;79(11-12):1752-60.

49.

The effect of oral contraceptive use on the prognosis of node positive breast cancer patients. German Breast Cancer Study Group.

Sauerbrei W, Blettner M, Schmoor C, Bojar H, Schumacher M.

Eur J Cancer. 1998 Aug;34(9):1348-51.

PMID:
9849415
50.

Dual-parameter immunoflow cytometry in diagnosis and follow-up of patients with bladder cancer.

Jankevicius F, Shibayama T, Decken K, Bojar H, Gerharz CD, Ebert T, Ackermann R, Schmitz-Dräger BJ.

Eur Urol. 1998 Dec;34(6):492-9.

PMID:
9831791

Supplemental Content

Support Center